Dr. Batheja joined the company in August 2020 as the Executive Director of CMC and was promoted to VP, Pharma R&D and CMC Regulatory in January 2023. From August 2016 to August 2020, she held several management positions in Analytical R&D and Quality at Progenics Pharmaceuticals now acquired by Lantheus, where she was involved in the development of the oncology pipeline. From July 2014 to August 2016, she was a Pharmaceutical Consultant working on NDA and ANDA for several different companies. She also held positions at Hi-Tech Pharmacal a subsidiary of Akorn from 2009 to 2014 and was successful in getting approval for several ophthalmic, nasal, and oral drugs.

Dr. Batheja received a Ph.D. from New York Medical College and a post-doctoral fellowship from the National Institute of Cancer.